Key result
CMOP chemotherapy resulted in remission of both large cell splenic lymphoma and the hypertrophic cardiomyopathy phenotype in a 10-year-old cat, with remission maintained at 21 months.
Case Report (n=1)
CMOP chemotherapy may resolve secondary hypertrophic cardiomyopathy phenotype in cats with large cell lymphoma and suspected cardiac involvement.
Answers are grounded in this paper and cite their sources.
May suggest reversible secondary HCM in feline lymphoma; hypothesis-generating and requires prospective validation before clinical adoption.
A 10‐year‐old female desexed domestic shorthair cat was diagnosed by the regular veterinarian with large cell splenic lymphoma in June 2020. A splenectomy was performed; however, complications postoperatively and the owner's willingness to pursue chemotherapy resulted in the patient being referred to the oncology department of a local multidisciplinary specialist hospital. At referral, a hypertrophic cardiomyopathy (HCM) phenotype was diagnosed post an episode of dyspnea. The patient was treated with CMOP (cyclophosphamide, mitoxantrone, vincristine and prednisone) chemotherapy, resulting in remission of the lymphoma and the HCM phenotype. Twenty‐one months out from treatment, the patient was still in remission with no evidence of heart disease.
No takes yet. Share an insight, caveat, or question.
Herbert et al. (2022) conducted a case report in Large cell splenic lymphoma and hypertrophic cardiomyopathy (HCM) phenotype (n=1). CMOP (cyclophosphamide, mitoxantrone, vincristine and prednisone) chemotherapy was evaluated on Remission of lymphoma and HCM phenotype. CMOP chemotherapy resulted in remission of both large cell splenic lymphoma and the hypertrophic cardiomyopathy phenotype in a 10-year-old cat, with remission maintained at 21 months.
Synapse has enriched 10 related papers. Consider them for comparative context: